clinical trial · NCT03342144
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
AbbVie·—·recruiting·n = 500
Chronic Lymphocytic Leukemia (CLL)
brief summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
started
Dec 4, 2017
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Dec 8, 2025
official title
Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol